Good
Mostly Aligned
Patient Risk:
Low
Summary
Core naming/identity claims are consistent with the provided label excerpt (CABOMETYX = cabozantinib). However, mechanistic and pharmacologic statements (e.g., pathway targeting, inhibition of tumor growth) are not supported by the provided label excerpts, so multiple claims cannot be verified against the supplied text.
Category Scores
Accurate Statements
Cabometyx is a brand name for the drug cabozantinib.
Provided label excerpt lists: "CABOMETYX (cabozantinib) — film-coated tablets".
A 'Cabometyx generic' would be a product whose active ingredient is cabozantinib.
Provided label excerpt identifies CABOMETYX active ingredient as cabozantinib (CABOMETYX (cabozantinib)).
Cabozantinib is a cancer medicine.
Provided label excerpt indicates CABOMETYX is indicated for treatment of advanced RCC, HCC, differentiated thyroid cancer, and neuroendocrine tumors (all cancer indications).
Unsupported Statements
Cabozantinib inhibits tumor growth.
No statement in the supplied label excerpts explicitly states cabozantinib inhibits tumor growth.
Cabozantinib targets multiple pathways involved in angiogenesis and tumor progression.
No mechanism-of-action/pathway description regarding angiogenesis or multiple pathways is included in the supplied label excerpts.
Cabozantinib is often sold as a generic drug under the same generic name, cabozantinib.
No market/generic availability/sales-frequency statements are included in the supplied label excerpts.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Unsupported mechanistic and market-availability claims are not directly related to dose/safety; the only supported claims are about product identity and cancer indications. No unsafe dosing, contraindication, or administration assertions were made.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Mechanism/pharmacologic efficacy and market/generic-availability claims are not supported by the provided label excerpts.
Suggested Improvement
Restrict statements to label-supported facts from the provided excerpts (e.g., CABOMETYX contains cabozantinib; labeled cancer indications) and avoid unquoted mechanistic claims (angiogenesis/tumor growth) and generic market frequency statements unless the label text supports them.